Csr astrazeneca


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Csr astrazeneca

  1. 1. •Ganesh Padhi (B047)•Richansh Kumar(B038)•Ritesh Kamal(B032)•Sushant Kumar(B039)•Mayank Shukla(B055)•B Kushal Kumar(B036)
  2. 2. Pharmaceutical sector United States-largest market with $289 billion annual sales EU and Japan are the next big markets in sales Markets like china, south Korea ,Russia and Mexico are growing at 81%. India- 3rd largest producer, Cardiovascular-50% & Diabetes -22%,Projected growth - $ 77 billion by 2012
  3. 3. Progress towards health-related MDGs Eradication of Hunger – Improvement in nutrition of undernourished children Reduction in Child Mortality at 2.7% every year Maternal Mortality Ratio(MMR) decreased by 34% Fighting HIV/AIDS, tuberculosis and malaria
  4. 4. Contd… Increase in population with better sanitation and safe drinking water from 77% to 87% Better access to affordable essential medicines in developing countries
  5. 5. Transparency Public Corruption private partnerships Ethical promotion Quality of and medicines marketing Issues in Pricingdiscounts pharma Clinical trails and sectordonations Management Patents and , Monitoring licenses and Accountabilit Policy y Neglected influence Medicines for diseases Advocacy disadvantage d individuals and and lobbying community
  6. 6. About Astrazeneca World’s fifth largest pharmaceutical company Dedicated to research, development , manufacturing and marketing of medicines in over 100 countries. Committed to sustainable development of business
  7. 7. Astrazeneca’s CSR approach Stakeholder based approach Mainly targeted employees Other stakeholders were suppliers, global community, environment and customers.
  8. 8. Employees Workforce diversity Work-life balance Safety, health and well being Health screening and other health activities
  9. 9. Suppliers Continuing risk assessments of suppliers Rolling out a programme of onsite audits of key suppliers Implementing plans to improve standards with certain suppliers Following up and verifying that progress is being made with suppliers Training staff on their standards
  10. 10. Customers Access to medicines for vulnerable individuals AstraZenecas Young Health Programme for 10-19 years of children Community sponsorships and charitable donations Patient assistance programmes to avail medicines free or at reduced prices.
  11. 11. OthersGlobal community Disaster reliefEnvironment Reduction in Greenhouse gas footprint Waste reduction Reduction in water usage Product environmental improvement Improvement in supply chain
  12. 12. Critical analysis Stakeholder approach Business responsibilities
  13. 13. Stakeholder approach Employees given more importance Suppliers have been maintained properly by adhering to global standards Some activities favoring environmental sustainability Special focus on access to medicines for needy and disadvantaged individuals Very few activities for global community and almost nothing for the local community
  14. 14. Business responsibilities Economic responsibilities – successful Legal responsibilities – fulfilled to considerable extent Ethical responsibilities – few activities ,needs to implement more activities and take it to a large scale Philanthropic responsibilities – nothing spectacular done as of yet
  15. 15. Conclusion Addresses concerns of majority of stakeholders Needs to work more towards suppliers and local community More of strategic CSR initiatives than philanthropic activities
  16. 16. Scope for future work Work environment improvement for employees Awareness programme for suppliers regarding environmental sustainability Implement environmental activities at a larger scale in more areas Invest more in R&D for innovative drugs and techniques for treatment Participate in community beneficial activities.